Background
==========

Multiple studies have shown associations between variants of the 5-lipoxygenase activating protein gene (*ALOX5AP*) and risk for ischemic stroke and myocardial infarction (MI) \[[@B1]-[@B9]\]. Two at-risk haplotypes (HapA and HapB) for stroke had been identified in the *ALOX5AP* gene \[[@B1],[@B10]\]. The single nucleotide polymorphisms (SNPs) associated with HapA are rs17222814, rs10507391, rs4769874, and rs9551963, and those associated with the HapB are rs17216473, rs10507391, rs9315050, and rs17222842. Different studies, however, reported conflicting results. The association of a 4-marker SNP haplotype in *ALOX5AP* with approximately 2-times increased risk of ischemic stroke and myocardial infarction was reported in an Icelandic population \[[@B1]\]. A similar risk of stroke was found in Chinese males \[[@B5]\], Japanese \[[@B8]\], and Europeans \[[@B2]\]. On the contrary, a study found no association of *ALOX5AP* variants with risk of MI or stroke in the United States (US) by Zee *et al.*\[[@B6]\], whereas another study in the US by Kaushal *et al.*\[[@B9]\] found a significant association with stroke among whites, but no association among blacks. These reports suggest that there might be variations between the populations of different ancestries in the association between *ALOX5AP* genetic variants and risk of stroke.

The purpose of this study was to study the possible association of 7 variants of *ALOX5AP*, rs4073259, rs4769874, rs9315050, rs9551963, rs10507391, rs9579646, and rs4147064 with ischemic stroke in the population with Han ancestry in northern China.

Material and methods
====================

Subjects
--------

The subjects included in this study were patients diagnosed with cerebral infarction from three hospitals including the Second Affiliated Hospital of Harbin Medical University, the Forth Affiliated Clinical Hospital of Harbin Medical University, and the First Affiliated Hospital of Harbin Medical University from October 2004 to May 2010. All cases were diagnosed using the Fourth edition of Cerebrovascular Disease Diagnostic Standards \[[@B11]\]. Patients who had endocrine related diseases, metabolic disorders, tumors, and cerebral hemorrhage were excluded from this study. The control group was composed of subjects who did not have cerebrovascular diseases themselves, and no family history of cerebrovascular diseases for a minimum of three generations. All the subjects in this study were from different families of Han ethnicity whose families have lived in the Northeastern part of China, including Heilongjiang, Jilin and Liaoning, for more than 3 generations. This study was approved by the Institutional Review Board of the Fourth Affiliated Clinical Hospital of Harbin Medical University and each participant provided written informed consent.

DNA extraction and genotyping
-----------------------------

DNA was extracted in a standard manner. Applied Biosystems® TaqMan® SNP Genotyping Assays were used for SNP genotyping following the manufacturer's instructions. In brief, one to 20 ng template DNA dissolved in 2.25 μL volume each well was loaded into 384-well plates for PCR. The reaction volume a total of 5 μL included 2.5 μL TaqMan Universal PCR master Mix (2x) and 0.25 μL 10× working stock of SNP genotyping assay buffer. The PCR reaction conditions were 95 °C for 10 min followed by 60 cycles of 92 °C for 15 sec and 60 °C for 1 min in an ABI 9700 PCR instrument. The genotyping data were collected by the ABI 9700 instrument. During SNP genotyping, duplicates/positive/negative controls were used as previously described \[[@B12]\].

Of the 4 HapA SNPs (rs17222814, rs10507391, rs4769874, and rs9551963), rs17222814 was not selected because in our preliminary study this SNP was shown to be almost monomorphic in the Chinese population. Thus, we selected 3 SNPs rs10507391, rs4769874, and rs9551963 from HapA for this study. Of the 4 HapB SNPs (rs17216473, rs10507391, rs9315050, and rs17222842), rs17222842 was excluded because it is monomorphic in the Chinese population, and rs17216473 was not selected because no significant association with stroke was noted in a preliminary study. The SNPs rs9579646 and rs4147064 were selected because they showed weak association with stroke in Israeli \[[@B2]\] and middle European populations \[[@B13]\], and rs4073259 was found to be associated with stroke in a preliminary study \[[@B12]\].

Statistical analysis
--------------------

Data are presented as mean ± standard deviation or number (percentage). Hardy-Weinberg equilibrium (HWE) testing was carried out for all 7 SNPs. Single markers in association with the disease were assessed using *χ*2 tests in Haploview Version 4.2 (Broad Institute, Cambridge, MA, USA). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression analysis. Statistical analysis was performed using by SPSS version 15.0 statistical software (SPSS, Inc., Chicago, IL, USA). A value of *P* \< 0.05 was considered statistically significant.

Results
=======

Patient demographics and disease characteristics
------------------------------------------------

The characteristics of ischemic stroke patients and controls are summarized in Table [1](#T1){ref-type="table"}. Patients with ischemic stroke were older and had higher triglyceride level than the controls (both *P* \< 0.001). About 16.5% (n = 39), 37.3% (n = 88), and 22.9% (n = 54) of patients with ischemic stroke had also heart disease, hypertension or diabetes, respectively, while no control had these diseases (All *P* \< 0.001). Cholesterol levels and gender distribution were not different between the groups.

###### 

Patient demographics and disease characteristics

                  **Ischemic Stroke Subjects (*n* = 236)**   **Healthy Control Subjects (*n* = 219)**   ***P***
  --------------- ------------------------------------------ ------------------------------------------ -----------
  Age (y)         62.86 ± 11.34                              50.36 ± 10.21                              \<0.001\*
  Triglycerides   1.75 ± 1.42                                1.38 ± 0.93                                \<0.001\*
  Cholesterol     5.07 ± 1.16                                5.00 ± 1.01                                0.503
  Male            125 (57.1)                                 145 (61.4)                                 0.390
  Heart disease   39 (16.5)                                  0                                          \<0.001\*
  Hypertension    88 (37.3)                                  0                                          \<0.001\*
  Diabetes        54 (22.9)                                  0                                          \<0.001\*

Data are presented as mean ± standard deviation or number (percentage).

rs9579646/SG13S106 G 211 (48) 258(55) 0.0504

Univariate analysis of SNP distribution between ischemic stroke patients and controls
-------------------------------------------------------------------------------------

The allele distribution of 7 SNPs of *ALOX5AP* was summarized in Table [2](#T2){ref-type="table"}. Only the frequency of rs4073259 SNP allele A was significantly different between ischemic stroke patients and the controls (48% vs 54%, *P* = 0.049). The frequency of rs9579646 allele G had a marginal p value between the two groups (48% vs 55%, *P* = 0.0504).

###### 

**The association of*ALOX5AP*SNP allele with ischemic stroke in northern Han Chinese**

  **\#**   **Public Name/SNP Name**   **Allele**   **Control Group (*n* = 219)**   **Case Group (*n* = 236)**   ***P***
  -------- -------------------------- ------------ ------------------------------- ---------------------------- ---------
  1        rs4147064/SG13S137         T            148 (34)                        186 (39)                     0.0882
                                      C            288 (66)                        286 (61)                      
  2        rs9579646/SG13S106         G            211 (48)                        258 (55)                     0.0504
                                      A            227 (52)                        214 (45)                      
  3        rs4073259/SG13S100         A            208 (48)                        255 (54)                     0.0487
                                      G            230 (53)                        217 (46)                      
  4        rs10507391/SG13S114        T            269 (62)                        304 (64)                     0.3979
                                      A            167 (38)                        168 (36)                      
  5        rs4769874/SG13S89          G            429 (98)                        464 (98)                     0.6887
                                      A            9 (2)                           8 (2)                         
  6        rs9315050/SG13S41          A            429 (98)                        464 (98)                     0.6887
                                      G            9 (2)                           8 (2)                         
  7        rs9551963/SG13S32          C            147 (34)                        188 (4)                      0.0564
                                      A            289 (66)                        284 (60)                      

Data are presented as numbers (percentages).

Then, the genotype distribution of ALOX5AP SNP in the ischemic stroke and the control groups is calculated (Table [3](#T3){ref-type="table"}). Individuals with a genotype of rs9551963 AC or a genotype of rs9579646 GG had higher risks of developing a cerebral infarction than individuals with genotype rs9551963 AA or genotype rs9579646 AA (OR = 1.50 (1.01-2.24), *P* = 0.046, OR = 1.73 (1.01-2.97), *P* = 0.047, respectively), But individuals with a genotype of GG in the rs4073259 SNP had a lower risk (0.57-fold) of developing a cerebral infarction than individuals with the AA genotype (95% CI 0.33-0.98, P = 0.044).

###### 

Genotype distribution in the stroke and control groups

  **\#**   **Public Name**   **Genotype**   **Control Group (*n* = 219)**   **Case Group (*n* = 236)**   **OR (95% CI)**    ***P***
  -------- ----------------- -------------- ------------------------------- ---------------------------- ------------------ ---------
  1        rs4147064         CC             97 (44)                         85 (36)                      Ref                \--
                             CT             94 (43)                         116 (49)                     1.41 (0.95-2.10)   0.092
                             TT             27 (12)                         35 (15)                      1.48 (0.83-2.64)   0.186
  2        rs9579646         AA             55 (25)                         46 (19)                      Ref                \--
                             AG             117 (53)                        122 (52)                     1.26 (0.79-2.01)   0.336
                             GG             47 (21)                         68 (29)                      1.73 (1.01-2.97)   0.047\*
  3        rs4073259         AA             45 (21)                         66 (28)                      Ref                \--
                             AG             118 (54)                        123 (52)                     0.72 (0.45-1.13)   0.152
                             GG             56 (26)                         47 (20)                      0.57 (0.33-0.98)   0.044\*
  4        rs10507391        AA             31 (14)                         28 (12)                      Ref                \--
                             AT             105 (48)                        112 (47)                     1.18 (0.66-2.10)   0.571
                             TT             82 (38)                         96 (41)                      1.30 (0.72-2.34)   0.389
  5        rs4769874         AG             9 (4)                           8 (3)                        Ref                \--
                             GG             210 (96)                        228 (97)                     1.09 (0.40-2.95)   0.872
  6        rs9315050         AA             210 (96)                        228 (97)                     Ref                \--
                             AG             9 (4)                           8 (3)                        0.92 (0.34-2.50)   0.872
  7        rs9551963         AA             99 (45)                         84 (36)                      Ref                \--
                             AC             91 (42)                         116 (49)                     1.50 (1.01-2.24)   0.046\*
                             CC             28 (13)                         36 (15)                      1.52 (0.85-2.69)   0.155

Data are presented as numbers (percentages) or odds ratio (OR) with 95% confidence interval (CI).

\*Significant difference between control and case groups (*P* \< 0.05).

For further analysis, a comparison of genotype distribution between the control group and case subgroups stratified into heart disease (n = 39), hypertension (n = 88), and diabetes (n = 54) is shown in Table [4](#T4){ref-type="table"}. In comparison to controls, rs4147064 genotype CT \[OR (95%CI) =1.872 (1.082-3.241)\] and rs9551963 genotype AC \[OR (95% CI = 2.015 (1.165-3.484)\] were positively significantly associated with cerebral infarction in patients with hypertension. Genotype rs9579646 GG \[OR (95% CI) = 2.926 (1.18-7.251)\] was positively significantly associated with, while genotype rs4073259 GG \[OR (95% CI) = 0.381 (0.157-0.922)\] was negatively significantly associated with cerebral infarction in patients with diabetes.

###### 

Comparison of genotype distribution between control and case groups stratified into heart disease, hypertension, and diabetes

  **\#**   **Public Name**   **Genotype**   **Control (*n* = 219)**   **Heart disease (*n* = 39)**   **Hypertension (*n* = 88)**   **Diabetes (*n* = 54)**                                    
  -------- ----------------- -------------- ------------------------- ------------------------------ ----------------------------- ------------------------- ---------- --------------------- ----------
  1        rs4147064         CC             97 (44%)                  1                                                            1                                    1                      
                             CT             94 (43%)                  1.096 (0.523-2.296)            0.8072                        1.872 (1.082-3.241)       0.0251\*   1.548 (0.8-2.995)     0.195
                             TT             27 (12%)                  1.347 (0.481-3.776)            0.5707                        1.596 (0.715-3.562)       0.2534     1.796 (0.725-4.448)   0.2055
  2        rs9579646         AA             55 (25%)                  1                                                            1                                    1                      
                             AG             117 (53%)                 1.067 (0.437-2.604)            0.8871                        1.171 (0.612-2.24)        0.6326     1.541 (0.655-3.623)   0.3215
                             GG             47 (21%)                  1.902 (0.726-4.981)            0.1908                        1.996 (0.977-4.077)       0.0578     2.926 (1.18-7.251)    0.0204\*
  3        rs4073259         AA             45 (21%)                  1                                                            1                                    1                      
                             AG             118 (54%)                 0.533 (0.241-1.176)            0.1189                        0.591 (0.328-1.062)       0.0787     0.526 (0.266-1.043)   0.066
                             GG             56 (26%)                  0.495 (0.189-1.297)            0.1523                        0.488 (0.238-1.001)       0.0504     0.381 (0.157-0.922)   0.0324\*
  4        rs10507391        AA             31 (14%)                  1                                                            1                                    1                      
                             AT             105 (48%)                 1.475 (0.469-4.64)             0.5058                        0.84 (0.398-1.776)        0.6485     1.771 (0.571-5.493)   0.3221
                             TT             82 (38%)                  1.417 (0.436-4.601)            0.5619                        1.105 (0.52-2.347)        0.7949     2.457 (0.793-7.614)   0.1192
  5        rs4769874         AG             9 (4%)                    1                                                            1                                    1                      
                             GG             210 (96%)                 0.704 (0.144-3.448)            0.6655                        1.079 (0.28-4.166)        0.9118     0.647 (0.166-2.526)   0.5312
  6        rs9315050         AA             210 (96%)                 1                                                            1                                    1                      
                             AG             9 (4%)                    1.42 (0.29-6.949)              0.6655                        0.926 (0.24-3.576)        0.9118     1.545 (0.396-6.029)   0.5312
  7        rs9551963         AA             99 (45%)                  1                                                            1                                    1                      
                             AC             91 (42%)                  1.156 (0.552-2.422)            0.701                         2.015 (1.165-3.484)       0.0122\*   1.792 (0.92-3.489)    0.0863
                             CC             28 (13%)                  1.326 (0.474-3.706)            0.5906                        1.44 (0.636-3.261)        0.3813     1.872 (0.753-4.652)   0.1771

Data are presented as numbers (percentages) or odds ratios (OR) with 95% confidence interval (CI).

\*Significant differences between controls and case subgroups (*P* \< 0.05).

Analysis of haplotype distribution between ischemic stroke patients and controls
--------------------------------------------------------------------------------

The haplotype distribution in the stroke and control groups are shown in Table [5](#T5){ref-type="table"}. Patients with haplotype rs9315050&rs9551963 AAAC had a higher risk to have ischemic stroke than haplotype rs9315050&rs9551963 AAAA (OR = 1.53 (1.02-2.29), *P* = 0.041).

###### 

Haplotype distribution in the stroke and control groups

  **Public Name**          **Haplotype**   **Control Groups (*n* = 219)**   **Case Groups (*n* = 236)**   **OR (95% CI)**   ***P***             
  ------------------------ --------------- -------------------------------- ----------------------------- ----------------- ------------------- ---------
  rs4147064 & rs9579646    CCAA            36 (17%)                         26 (11%)                      Ref               \--                 
                                           CCAG                             50 (23%)                      40 (17%)          1.11 (0.58-2.13)    0.759
                                           CCGG                             11 (5%)                       19 (8%)           2.39 (0.98-5.87)    0.057
                                           CTAA                             15 (7%)                       20 (8%)           1.85 (0.80-4.27)    0.152
                                           CTAG                             53 (24%)                      64 (27%)          1.67 (0.90-3.12)    0.105
                                           CTGG                             26 (12%)                      32 (14%)          1.70 (0.83-3.51)    0.148
                                           TTAA                             4 (2%)                        0 (0%)            \--                 \--
                                           TTAG                             13 (6%)                       18 (8%)           1.92 (0.80-4.59)    0.144
                                           TTGG                             10 (5%)                       17 (7%)           2.35 (0.93-5.97)    0.071
  rs4073259 & rs10507391   AAAT            6 (3%)                           2 (1%)                        Ref               \--                 
                                           AATT                             39 (18%)                      64 (27%)          4.92 (0.95-25.61)   0.058
                                           AGAA                             2 (1%)                        3 (1%)            4.50 (0.41-49.63)   0.219
                                           AGAT                             75 (34%)                      90 (38%)          3.60 (0.71-18.36)   0.123
                                           AGTT                             40 (18%)                      30 (13%)          2.25 (0.42-11.94)   0.341
                                           GGAA                             29 (13%)                      25 (11%)          2.59 (0.48-13.98)   0.27
                                           GGAT                             24 (11%)                      20 (8%)           2.50 (0.45-13.78)   0.293
                                           GGTT                             3 (1%)                        2 (1%)            2.00 (0.18-22.06)   0.571
  rs9315050 & rs9551963    AAAA            99 (45%)                         84 (36%)                      Ref               \--                 
                                           AAAC                             85 (39%)                      110 (47%)         1.53 (1.02-2.29)    0.041\*
                                           AACC                             26 (12%)                      34 (14%)          1.54 (0.86-2.77)    0.149
                                           AGAC                             6 (3)%                        6 (3%)            1.18 (0.37-3.79)    0.783
                                           AGCC                             2 (1%)                        2 (1%)            1.18 (0.16-8.55)    0.871

Data are presented as numbers (percentages) or odds ratios (OR) with 95% confidence interval (CI).

\*Significant differences between control and case groups (*P* \< 0.05).

We further did linkage disequllibrium analysis and found significant linkage between rs9315050 *vs.* rs9551963, rs4073259 *vs.* rs10507391, and rs9579646 *vs.* rs4147064 (D' = 1.0, D' = 0.911, and D' = 0.376, respectively, Figure [1](#F1){ref-type="fig"}).

![**Analysis of haplotype distribution between ischemic stroke patients and controls.** Linkage was found to be significant between rs9315050 *vs.* rs9551963, rs4073259 *vs.* rs10507391, and rs9579646 *vs.* rs4147064 (D' = 1.0, D' = 0.911, and D' = 0.376, respectively).](1471-2350-13-61-1){#F1}

Discussion
==========

Our findings indicate that the A allele in rs4073259 is markedly increased in cerebral infarction patients in comparison to control subjects of Han ancestry in northern China. Genotype rs9579646 GG and rs9551963 AC were positively, while rs4073259 GG was negatively associated with cerebral infarction. Haplotypes rs9315050 & rs9551963 AAAC were positively associated with cerebral infarction. Furthermore, genotypes rs4147064 CT and rs9551963 AC were associated with cerebral infarction in patients with hypertension, while rs9579646 GG and rs4073259 GG were associated with cerebral infarction in patients with diabetes. The findings suggest that SNP rs4073259 of the *ALOX5AP* gene is associated with developing cerebral infarction in this cohort, although the possibility that it is a functional variant cannot be ruled out. Although we found no marked difference in the frequency of alleles of other *ALOX5AP* SNPs tested between the control and case groups studied, we found significant differences of genotype frequency of other *ALOX5AP* SNPs between the control and case subjects, suggesting that they might play a role in the pathogenesis of cerebral infarction in the Han population of northern China.

Microarray assays have revealed positive linkage domains associated with cardiovascular and cerebrovascular diseases which locate at 13p12-13 \[[@B1]-[@B3],[@B10],[@B14]\]. The ALOX5AP gene is located at bands 2 and 3 of region 1 of the long arm of chromosome 13, and encodes 5-lipoxygenase activating protein (FLAP) which regulates the synthesis of leukotrienes \[[@B15]\]. An increase in the production of leukotrienes and resulting inflammatory changes in local blood vessels may be associated with development of atherosclerosis \[[@B4],[@B16]-[@B19]\]. Whether the rs4073259 SNP alters FLAP warrants further study.

The association between the genetic polymorphism of *ALOX5AP* and the occurrence of cerebral infarction has been previously reported, but discrepancies between studies carried out in different populations have been noted. For example, Kaushal *et al.*\[[@B9]\] found that rs957646 and rs769874 were significantly associated with stroke in whites in the US, but no association was found in blacks. Another US study by Zee *et al.*\[[@B6]\] found no association of HapA or Hap B with stroke. Meschia *et al.*\[[@B4]\] found no association of *ALOX5AP* variants and ischemic stroke in a US population, Zhang *et al.*\[[@B5]\] reported the *ALOX5AP* variant SG13S114T/A was associated with increased risk of stroke in Chinese males, and Linsel-Nitschke *et al.*\[[@B20]\] found HapB was associated with an increased risk of myocardial infarction in a German population. Ji *et al.*\[[@B21]\] in a recent study reported that the −581_582 Ins A polymorphism in *ALOX5AP* might be a genetic risk factor for ischemic stroke in the Chinese Han population. The lack of consistency in available studies also suggests a limit of the analytical methodologies used in these studies, the population association test. A better refined methodology, such as the Family base association test (FBAT), may be needed to provide consistent results \[[@B22]\].

Zintaras *et al.*\[[@B13]\] performed a meta-analysis in 2009 including all studies of *ALOX5AP* genotyping (5,194 stroke cases and 4,566 controls). The authors found significant heterogeneity among studies (PQ = 0.03, I2 = 63%), a non-significant association between the HapA and stroke risk (random-effects \[RE\] OR = 1.13, 95% CI 0.88-1.45), and no association of HapB with stroke risk (RE OR = 1.03, 95% CI 0.77-1.37). They also reported that the SG13S114, SG13S89, SG13S25, SG13S32, SG13S35, and SG13S42 polymorphisms were not associated with stroke. The authors concluded that to date, the cumulated evidence did not support an association of *ALOX5AP* variants and risk of stroke, though they cautioned that the conclusion was based on a relatively small number of studies.

The primary limitation of this study is the relatively low case number, especially in stratification based on genotypes. Further study with a larger population is required to confirm the findings. In addition, we did not study SNPs from other susceptible genes, *e.g.*, phosphodiesterase 4D (*PDE4D*) in which some of the SNPs have been shown to be associated with the development of cerebral infarction \[[@B4]\].

Conclusions
===========

In summary, our results indicate the *ALOX5AP* SNP A allele in rs4073259, genotype rs9579646 GG, rs9551963 AC, and haplotype rs9315050&rs9551963 AAAC were associated with an increased risk of ischemic stroke in the Han population, while rs4073259 GG was associated with a decreased risk. Genotype rs4147064 CT and rs9551963 AC were positively significantly associated with cerebral infarction in patients with hypertension while genotype rs9579646 GG was positively significantly associated with, while genotype rs4073259 GG was negatively significantly associated with, cerebral infarction in patients with diabetes. However, more studies with large sample size are needed to detect the extended haplotype, and further confirm whether other SNPs of the *ALOX5AP* gene are associated with cerebral infarction.
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